Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Walter Bonfig - , Klinikum Wels - Grieskirchen GmbH, Technical University of Munich (Author)
  • Friedhelm Roehl - , Otto von Guericke University Magdeburg (Author)
  • Stefan Riedl - , University of Vienna (Author)
  • Jürgen Brämswig - , University of Münster (Author)
  • Annette Richter-Unruh - , University of Münster (Author)
  • Susanne Fricke-Otto - , Helios Hospital Group (Author)
  • Angela Hübner - , Department of Paediatrics, University Hospital Carl Gustav Carus Dresden, TUD Dresden University of Technology (Author)
  • Markus Bettendorf - , Heidelberg University  (Author)
  • Eckhard Schönau - , University of Cologne (Author)
  • Helmut Dörr - , Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • Reinhard W. Holl - , Ulm University (Author)
  • Klaus Mohnike - , Otto von Guericke University Magdeburg (Author)

Abstract

Sodium chloride supplementation in saltwasting congenital adrenal hyperplasia (CAH) is generally recommended in infants, but its implementation in routine care is very heterogeneous. Objective: To evaluate oral sodium hloride supplementation, growth, and hydrocortisone and fludrocortisone dose in infants with salt-wasting CAH due to 21-hydroxylase in 311 infants from the AQUAPE CAH database. Results: Of 358 patients with classic CAH born between 1999 and 2015, 311 patients had salt-wasting CAH (133 females, 178 males). Of these, 86 patients (27.7%) received oral sodium chloride supplementation in a mean dose of 0.9± 1.4 mmol/kg/day (excluding nutritional sodium content) during the first year of life. 225 patients (72.3%) were not treated with sodium chloride. The percentage of sodium chloride-supplemented patients rose from 15.2% in children born 1999-2004 to 37.5% in children born 2011- 2015. Sodium chloride-supplemented and -unsupplemented infants did not significantly differ in hydrocortisone and fludrocortisone dose, target height-corrected height-SDS.

Details

Original languageEnglish
Pages (from-to)7-12
Number of pages6
JournalHormone Research in Paediatrics
Volume89
Issue number1
Publication statusPublished - 1 Feb 2018
Peer-reviewedYes

External IDs

PubMed 29073619

Keywords

Sustainable Development Goals

Keywords

  • Congenital adrenal hyperplasia, Fludrocortisone, Hydrocortisone, Salt-wasting congenital adrenal hyperplasia, Sodium chloride supplementation